Terns Pharmaceuticals

TERN

Market cap $736M

FOSTER CITY, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2025 equity inducement awards to four new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns.

While oncology is the largest therapeutic area in the pharmaceutical industry by revenue, the anti-obesity space has grabbed the most attention over the past couple of years. This niche is still in its infancy, though, and it is projected to grow rapidly at least through the end of the decade.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:00 AM EDT Company Participants Amy Burroughs - CEO & Director Scott Harris - Chief Development Officer Conference Call Participants Kelly McCarthy Presentation Kelly McCarthy All right. Thanks, everybody, for joining us.

Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript Company Participants Amy Burroughs - CEO & Director Emil Kuriakose - Chief Medical Officer Scott Harris - Chief Development Officer Conference Call Participants Ritu Baral - TD Cowen, Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Eliana Merle - UBS Investment Bank, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Presentation Operator Good day, and thank you for standing by.

FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced it will host an investor educational webinar on TERN-701 in advance of the data release expected in fourth quarter of 2025.

Terns (TERN) Q2 Net Loss Narrows 16%

Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25

FOSTER CITY, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of August 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended.

Terns Pharmaceuticals, Inc. offers two differentiated late-stage assets—TERN-701 for CML and TERN-601 for obesity—with major data catalysts expected in Q4 2025. TERN-701 shows early signs of best-in-class potential in CML, with encouraging molecular response and safety data versus Novartis' Scemblix. TERN-601's oral GLP-1 candidate demonstrated promising weight loss and tolerability, targeting a massive obesity market with room for differentiated entrants.

Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024